Form 4: Dyne Therapeutics Director Dirk Kersten Reports Sale of Shares

Director Dirk Kersten reports the sale of Dyne Therapeutics (DYN) shares held by Forbion Capital Fund IV Cooperatief U.A. and ForDyne B.V. through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Dirk Kersten, a director of Dyne Therapeutics, filed a Form 4 disclosing sales of common stock.
• The sales were executed on August 16, 2024, and August 19, 2024.
• The transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (FCF IV) on April 9, 2024.
• A total of 162,619 shares were sold on August 16, 2024, at weighted average prices ranging from $44.52 to $46.19.
• A total of 126,032 shares were sold on August 19, 2024, at weighted average prices ranging from $45.10 to $46.59.
• The shares are held by FCF IV and ForDyne B.V.
• Kersten disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of share sales under a pre-arranged trading plan. It doesn't inherently indicate positive or negative news about the company's performance.

Risks

• The Form 4 filing indicates sales of shares by a director, which could be perceived negatively by investors.

Industry Context

Form 4 filings are standard disclosures for insiders trading in their company's stock, providing transparency to the market.

Key Dates